Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review

Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review

Background: More and more novel anticancer drugs have been approved for patients with hematological malignancies in recent years, but HBV reactivation (HBV-R) data in this population is very scarce. This study aimed to evaluated HBV-R risk in patients with hematological malignancies receiving novel...

Full description

Bibliographic Details
Main Authors: Zheng Yan, Xu-Feng Luo, Shu-Na Yao, Hai-Ying Wang, Jun-Feng Chu, Shuang Zhao, Ming Song, Xu-Dong Wei, Ke-Shu Zhou, Yu-Fu Li, Wen-Ping Zhou, Jiu-Yang Zhang, Pei-Pei Zhang, Li-Li Zhou, Xian-Wei Wang, Zhi-Hua Yao, Yan-Yan Liu
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Journal of Microbiology, Immunology and Infection
Subjects:
Hematological malignancy
HBV reactivation
Lymphoma
Novel anticancer drug
Incidence
Online Access:http://www.sciencedirect.com/science/article/pii/S1684118223000804

Internet

http://www.sciencedirect.com/science/article/pii/S1684118223000804

Similar Items